Mukesh Thawani, MD
Internal Medicine · Roseburg, ORNPI 1174716427
Payments from drug & device makers
Across 34 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$131
- AstraZeneca$64
- Amgen$60
- Takeda Pharmaceuticals U.S.A., Inc.$50
- OPKO Pharmaceuticals, LLC$39
- Madrigal Pharmaceuticals$38
- plus $317 from 15 others
What the payments were for
- Food & beverage$65994%
- Education$396%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $131 |
| AstraZeneca | 3 | $64 |
| Amgen(2 entities) | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| OPKO Pharmaceuticals, LLC | 2 | $39 |
| Madrigal Pharmaceuticals | 1 | $38 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Lundbeck LLC | 2 | $30 |
| Scpharmaceuticals Inc. | 1 | $29 |
| Bayer | 1 | $25 |
| GSK | 1 | $23 |
| Akebia Therapeutics Inc | 1 | $23 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Sanofi | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$698 in reported general payments places this provider in the 85th percentile of 1,363 internal medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefpodoxime Proxetil | 26 | $779 |
| ClopidogrelClopidogrel Bisulfate | 20 | $221 |
| Cefdinir | 25 | $209 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $176 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $170 |
| Atorvastatin Calcium | 18 | $165 |
| Metoprolol Tartrate | 13 | $129 |
| Metoprolol Succinate | 15 | $129 |
| Losartan Potassium | 17 | $124 |
| Dexamethasone | 13 | $97 |
| Prednisone | 19 | $87 |
| Amlodipine Besylate | 15 | $82 |
| Furosemide | 18 | $55 |
| Tramadol Hcl | 23 | $53 |
| Azithromycin | 13 | $47 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Roseburg
- Stephen SpurgeonPortland$8.6M
- Drissana TranSalem$4.8M
- James BergtholdPortland$4.7M
- Stephen FortmannPortland$3.3M
- Maryann ConradPortland$2.7M
- Brian CurtisCorvallis$2.4M
- Jennifer SaultzPortland$1.9M
- Elizabeth LilesHillsboro$1.9M
- Marc UemuraEugene$1.6M
- Michael ChenStayton$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.